{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:30:25Z","timestamp":1794047425435,"version":"4.8.0"},"reference-count":41,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"8","license":[{"start":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T00:00:00Z","timestamp":1676505600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Therapy-resistant viral reactivations contribute significantly to mortality after hematopoietic stem cell transplantation. Adoptive cellular therapy with virus-specific T cells (VST) has shown efficacy in various single-center trials. However, the scalability of this therapy is hampered by laborious production methods. In this study we describe the in-house production of VST in a closed system (CliniMACS Prodigy\u00ae system, Miltenyi Biotec). In addition, we report the efficacy in 26 patients with viral disease following hematopoietic stem cell transplantation in a retrospective analysis (adenovirus, n=7; cytomegalovirus, n=8; Epstein-Barr virus, n=4; multi-viral, n=7). The production of VST was successful in 100% of cases. The safety profile of VST therapy was favorable (n=2 grade 3 and n=1 grade 4 adverse events; all three were reversible). A response was seen in 20 of 26 patients (77%). Responding patients had a significantly better overall survival than patients who did not respond (P&lt;0.001). Virus-specific symptoms were reduced or resolved in 47% of patients. The overall survival of the whole cohort was 28% after 6 months. This study shows the feasibility of automated VST production and safety of application. The scalability of the CliniMACS Prodigy\u00ae device increases the accessibility of VST treatment.<\/jats:p>","DOI":"10.3324\/haematol.2022.281996","type":"journal-article","created":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T03:43:33Z","timestamp":1676519013000},"page":"2080-2090","source":"Crossref","is-referenced-by-count":14,"title":["Automated production of specific T cells for treatment of refractory viral infections after allogeneic stem cell transplantation"],"prefix":"10.3324","volume":"108","author":[{"given":"Amadeus T","family":"Heinz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friso G.J.","family":"Calkoen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Derbich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea","family":"Miltner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Seitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Doering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Braun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Atar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Schumm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Heubach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Marie","family":"Arendt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ansgar","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedhelm R","family":"Schuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Meisel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Strahm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juergen","family":"Finke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Heineking","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Stetter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerda","family":"Silling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Stachel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Gruhn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus-Michael","family":"Debatin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juergen","family":"Foell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes H","family":"Schulte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilhelm","family":"Woessmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Mauz-K\u00f6rholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Tischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Feuchtinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupert","family":"Handgretinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2023,2,16]]},"reference":[{"key":"50310","doi-asserted-by":"crossref","unstructured":"Sobocinski KA, Horowitz MM, Rowlings PA. Bone marrow transplantation\u20141994: a report from the International Bone Marrow Transplant Registry and the North American Autologous Bone Marrow Transplant Registry. J Hematother. 1994; 3(2):95-102.","DOI":"10.1089\/scd.1.1994.3.95"},{"key":"50311","doi-asserted-by":"crossref","unstructured":"Dykewicz CA. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis. 2001; 33(2):139-144.","DOI":"10.1086\/321805"},{"key":"50312","doi-asserted-by":"crossref","unstructured":"Kim N, Nam YS, Im KI. Robust production of cytomegalovirus pp65-specific T cells using a fully automated IFN-\u03b3 cytokine capture system. Transfus Med Hemother. 2018; 45(1):13-22.","DOI":"10.1159\/000479238"},{"key":"50313","doi-asserted-by":"crossref","unstructured":"Ross SA, Novak Z, Pati S, Boppana SB. Overview of the diagnosis of cytomegalovirus infection. Infect Disord Drug Targets. 2011; 11(5):466-474.","DOI":"10.2174\/187152611797636703"},{"key":"50314","doi-asserted-by":"crossref","unstructured":"Leen AM, Tripic T, Rooney CM. Challenges of T cell therapies for virus-associated diseases after hematopoietic stem cell transplantation. Expert Opin Biol Ther. 2010; 10(3):337-351.","DOI":"10.1517\/14712590903456003"},{"key":"50315","doi-asserted-by":"crossref","unstructured":"Allen UD, Preiksaitis JK. Epstein-Barr virus and posttransplant lymphoproliferative disorder in solid organ transplantation. Am J Transplant. 2013; 13:107-120.","DOI":"10.1111\/ajt.12104"},{"key":"50316","doi-asserted-by":"crossref","unstructured":"Chakrabarti S, Mautner V, Osman H. Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery. Blood. 2002; 100(5):1619-1627.","DOI":"10.1182\/blood-2002-02-0377"},{"key":"50317","doi-asserted-by":"crossref","unstructured":"Lucas KG, Burton RL, Zimmerman SE. Semiquantitative Epstein-Barr virus (EBV) polymerase chain reaction for the determination of patients at risk for EBV-induced lymphoproliferative disease after stem cell transplantation. Blood. 1998; 91(10):3654-3661.","DOI":"10.1182\/blood.V91.10.3654.3654_3654_3661"},{"key":"50318","doi-asserted-by":"crossref","unstructured":"Sukdolak C, Tischer S, Dieks D. CMV-, EBV- and ADV-specific T cell immunity: screening and monitoring of potential third-party donors to improve post-transplantation outcome. Biol Blood Marrow Transplant. 2013; 19(10):1480-1492.","DOI":"10.1016\/j.bbmt.2013.07.015"},{"key":"50319","doi-asserted-by":"crossref","unstructured":"Travi G, Pergam SA. Cytomegalovirus pneumonia in hematopoietic stem cell recipients. J Intensive Care Med. 2014; 29(4):200-212.","DOI":"10.1177\/0885066613476454"},{"key":"50320","doi-asserted-by":"crossref","unstructured":"Cho SY, Lee DG, Kim HJ. Cytomegalovirus infections after hematopoietic stem cell transplantation: current status and future immunotherapy. Int J Mol Sci. 2019; 20(11):2666.","DOI":"10.3390\/ijms20112666"},{"key":"50321","doi-asserted-by":"crossref","unstructured":"Yusuf U, Hale GA, Carr J. Cidofovir for the treatment of adenoviral infection in pediatric hematopoietic stem cell transplant patients. Transplantation. 2006; 81(10):1398-1404.","DOI":"10.1097\/01.tp.0000209195.95115.8e"},{"key":"50322","doi-asserted-by":"crossref","unstructured":"Marty FM, Ljungman P, Chemaly RF. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med. 2017; 377(25):2433-2444.","DOI":"10.1056\/NEJMoa1706640"},{"key":"50323","doi-asserted-by":"crossref","unstructured":"Goodrich JM, Mori M, Gleaves CA. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med. 1991; 325(23):1601-1607.","DOI":"10.1056\/NEJM199112053252303"},{"key":"50324","doi-asserted-by":"crossref","unstructured":"Kinchington PR, Araullo-Cruz T, Vergnes JP, Yates K, Gordon YJ. Sequence changes in the human adenovirus type 5 DNA polymerase associated with resistance to the broad spectrum antiviral cidofovir. Antiviral Res. 2002; 56(1):73-84.","DOI":"10.1016\/S0166-3542(02)00098-0"},{"key":"50325","doi-asserted-by":"crossref","unstructured":"Lindemans CA, Leen AM, Boelens JJ. How I treat adenovirus in hematopoietic stem cell transplant recipients. Blood. 2010; 116(25):5476-5485.","DOI":"10.1182\/blood-2010-04-259291"},{"key":"50326","doi-asserted-by":"crossref","unstructured":"Smith IL, Cherrington JM, Jiles RE, Fuller MD, Freeman WR, Spector SA. High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes. J Infect Dis. 1997; 176(1):69-77.","DOI":"10.1086\/514041"},{"key":"50327","doi-asserted-by":"crossref","unstructured":"Feucht J, Joachim L, Lang P, Feuchtinger T. Adoptive T-cell transfer for refractory viral infections with cytomegalovirus, Epstein-Barr virus or adenovirus after allogeneic stem cell transplantation. Klin Padiatr. 2013; 225(3):164-169.","DOI":"10.1055\/s-0033-1333749"},{"key":"50328","doi-asserted-by":"crossref","unstructured":"Feuchtinger T, Matthes-Martin S, Richard C. Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation. Br J Haematol. 2006; 134(1):64-76.","DOI":"10.1111\/j.1365-2141.2006.06108.x"},{"key":"50329","doi-asserted-by":"crossref","unstructured":"Feuchtinger T, Opherk K, Bethge WA. Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. Blood. 2010; 116(20):4360-4367.","DOI":"10.1182\/blood-2010-01-262089"},{"key":"50330","doi-asserted-by":"crossref","unstructured":"Saglio F, Hanley PJ, Bollard CM. The time is now: moving toward virus-specific T cells after allogeneic hematopoietic stem cell transplantation as the standard of care. Cytotherapy. 2014; 16(2):149-159.","DOI":"10.1016\/j.jcyt.2013.11.010"},{"key":"50331","doi-asserted-by":"crossref","unstructured":"Gerdemann U, Christin AS, Vera JF. Nucleofection of DCs to generate multivirus-specific T cells for prevention or treatment of viral infections in the immunocompromised host. Mol Ther. 2009; 17(9):1616-1625.","DOI":"10.1038\/mt.2009.140"},{"key":"50332","doi-asserted-by":"crossref","unstructured":"K\u00e1llay K, Kassa C, R\u00e9ti M. Early experience with CliniMACS Prodigy CCS (IFN-gamma) system in selection of virus-specific T cells from third-party donors for pediatric patients with severe viral infections after hematopoietic stem cell transplantation. J Immunother. 2018; 41(3):158-163.","DOI":"10.1097\/CJI.0000000000000197"},{"key":"50333","doi-asserted-by":"crossref","unstructured":"Feucht J, Opherk K, Lang P. Adoptive T-cell therapy with hexon-specific Th1 cells as a treatment of refractory adenovirus infection after HSCT. Blood. 2015; 125(12):1986-1994.","DOI":"10.1182\/blood-2014-06-573725"},{"key":"50334","doi-asserted-by":"crossref","unstructured":"Gerdemann U, Vera JF, Rooney CM, Leen AM. Generation of multivirus-specific T cells to prevent\/treat viral infections after allogeneic hematopoietic stem cell transplant. J Vis Exp. 2011; 51:2736.","DOI":"10.3791\/2736-v"},{"key":"50335","doi-asserted-by":"crossref","unstructured":"Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science. 1992; 257(5067):238-241.","DOI":"10.1126\/science.1352912"},{"key":"50336","doi-asserted-by":"crossref","unstructured":"Priesner C, Esser R, Tischer S. Comparative analysis of clinical-scale IFN-\u03b3-positive T-cell enrichment using partially and fully integrated platforms. Front Immunol. 2016; 7:393.","DOI":"10.3389\/fimmu.2016.00393"},{"key":"50337","doi-asserted-by":"crossref","unstructured":"Icheva V, Kayser S, Wolff D. Adoptive transfer of Epstein-Barr virus (EBV) nuclear antigen 1-specific T cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation. J Clin Oncol. 2013; 31(1):39-48.","DOI":"10.1200\/JCO.2011.39.8495"},{"key":"50338","doi-asserted-by":"crossref","unstructured":"Pei XY, Zhao XY, Chang YJ. Cytomegalovirus-specific T-cell transfer for refractory cytomegalovirus infection after haploidentical stem cell transplantation: the quantitative and qualitative immune recovery for cytomegalovirus. J Infect Dis. 2017; 216(8):945-956.","DOI":"10.1093\/infdis\/jix357"},{"key":"50339","doi-asserted-by":"crossref","unstructured":"Papadopoulou A, Gerdemann U, Katari UL. Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT. Sci Transl Med. 2014; 6(242):242.","DOI":"10.1126\/scitranslmed.3008825"},{"key":"50340","doi-asserted-by":"crossref","unstructured":"Kaeuferle T, Krauss R, Blaeschke F, Willier S, Feuchtinger T. Strategies of adoptive T -cell transfer to treat refractory viral infections post allogeneic stem cell transplantation. J Hematol Oncol. 2019; 12(1):13.","DOI":"10.1186\/s13045-019-0701-1"},{"key":"50341","doi-asserted-by":"crossref","unstructured":"Lion T. Adenovirus infections in immunocompetent and immunocompromised patients. Clin Microbiol Rev. 2014; 27(3):441-462.","DOI":"10.1128\/CMR.00116-13"},{"key":"50342","unstructured":"Ljungman P. Cytomegalovirus pneumonia: presentation, diagnosis, and treatment. Semin Respir Infect. 1995; 10(4):209-215."},{"key":"50343","doi-asserted-by":"crossref","unstructured":"Kampmann B, Cubitt D, Walls T. Improved outcome for children with disseminated adenoviral infection following allogeneic stem cell transplantation. Br J Haematol. 2005; 130(4):595-603.","DOI":"10.1111\/j.1365-2141.2005.05649.x"},{"key":"50344","doi-asserted-by":"crossref","unstructured":"Haque T, Wilkie GM, Jones MM. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood. 2007; 110(4):1123-1131.","DOI":"10.1182\/blood-2006-12-063008"},{"key":"50345","doi-asserted-by":"crossref","unstructured":"Withers B, Clancy L, Burgess J. Establishment and operation of a third-party virus-specific T cell bank within an allogeneic stem cell transplant program. Biol Blood Marrow Transplant. 2018; 24(12):2433-2442.","DOI":"10.1016\/j.bbmt.2018.08.024"},{"key":"50346","doi-asserted-by":"crossref","unstructured":"Jiang W, Clancy LE, Avdic S. Third-party CMV- and EBV-specific T-cells for first viral reactivation after allogeneic stem cell transplant. Blood Adv. 2022; 6(17):4949-4966.","DOI":"10.1182\/bloodadvances.2022007103"},{"key":"50347","doi-asserted-by":"crossref","unstructured":"Pei X-Y, Liu X-F, Zhao X-Y. Comparable anti-CMV responses of transplant donor and third-party CMV-specific T cells for treatment of CMV infection after allogeneic stem cell transplantation. Cell Mol Immunol. 2022; 19(4):482-491.","DOI":"10.1038\/s41423-021-00829-y"},{"key":"50348","doi-asserted-by":"crossref","unstructured":"Rubinstein JD, Lutzko C, Leemhuis T. Scheduled administration of virus-specific T cells for viral prophylaxis after pediatric allogeneic stem cell transplant. Blood Adv. 2022; 6(9):2897-2907.","DOI":"10.1182\/bloodadvances.2021006309"},{"key":"50349","doi-asserted-by":"crossref","unstructured":"Heslop HE. How I treat EBV lymphoproliferation. Blood. 2009; 114(19):4002-4008.","DOI":"10.1182\/blood-2009-07-143545"},{"key":"50350","doi-asserted-by":"crossref","unstructured":"Hashimoto M, Kamphorst AO, Im SJ. CD8 T cell exhaustion in chronic infection and cancer: opportunities for interventions. Ann Rev Med. 2018; 69(1):301-318.","DOI":"10.1146\/annurev-med-012017-043208"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2022.281996\/75344","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2022.281996\/75874","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/10980\/75344","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:03:33Z","timestamp":1794045813000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2022.281996"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,16]]},"references-count":41,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,8,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2022.281996","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2,16]]}}}